跨阿尔茨海默氏病谱的功能性和结构性脑部异常的多模式元分析证据
Xinyue Tang1, Zixuan Guo1, Guanmao Chen1
1Medical Imaging Center, First Affiliated Hospital of Jinan University, Guangzhou 510630, China; Institute of Molecular and Functional Imaging, Jinan University, Guangzhou 510630, China.
Ageing research reviews
|February 23, 2024
概括
阿尔茨海默氏症 (AD) 显示大脑功能和结构发生变化,特别是在后带状回环和副海马回环中. 这些变化与遗传和神经递质系统缺陷有关,为AD病理生理学提供了新的见解.
科学领域:
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病 (AD) 频谱与与功能活动和皮层厚度有关的不一致的神经成像发现有关.
- 在AD中,这些大脑变化,基因表达和神经递质系统之间的联系在很大程度上仍未被探索.
研究的目的:
- 进行元分析,确定AD和临床前AD中大脑活动和皮质厚度的多模式差异.
- 研究这些变化与转录特征和神经递质系统的相关性.
主要方法:
- 低频波动 (ALFF) /分数ALFF (fALFF) 和皮层厚度 (CT) 研究幅度的元分析.
- 使用基于种子的d绘图与对象图像的变换软件.
- 从艾伦人类大脑地图和神经递质地图使用JuSpace工具箱集成的转录数据.
主要成果:
- 患有阿尔茨海默症的患者在带回形 (PCC) /前回形和角回形中呈现ALFF/fALFF降低,在带回形 (PHG) 中呈现ALFF/fALFF增加.
- 临床前的阿尔茨海默病显示左侧前骨的ALFF/fALFF降低.
- 艾滋病患者在PHG,PCC,轨道前皮层,感觉运动和部区域的CT下降,G蛋白合受体信号传递和离子通道活性的遗传丰富,以及与多巴胺基,血清胺基和GABAergic系统的关联.
结论:
- 在PCC/precuneus和PHG的融合功能和结构变化,以及感觉/运动区域的皮质稀释,是AD的特征.
- 在临床前阿尔茨海默病中观察到先性活性的减少.
- 遗传和神经递质缺陷是阿尔茨海默氏症全谱大脑损伤的基础,提供了新的病理生理学见解.
相关概念视频
Alzheimer's Disease: Overview
484
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
484
Alzheimer's Disease: Treatment
189
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
189


